ESG Report 2025

According to data from the International Diabetes Federation and the Federal Pharmacy Council of Brazil, Brazil ranks sixth globally in the number of adults with diabetes, with approximately 16 million patients and a prevalence rate of about 11%. Brazil has long relied on imported insulin, facing the dual challenges of rising drug costs and supply chain instability. The cost of diabetes treatment imposes a heavy economic burden on Brazil's healthcare system. The successful entry of the Group's insulin products into the Brazilian market will provide local patients with more affordable treatment options. In the future, the Group will align with the national “Belt and Road” development strategy, focusing on diabetes products to continuously expand the overseas presence of its human formulation products in countries and regions along the route. TUL Insulin Exported to Brazil In addition, the Group has accelerated the global expansion of its animal healthcare business, progressively advancing or completing product registrations in multiple countries and regions worldwide, covering both food-producing and companion animal medicines. The Group is committed to becoming a global leader in animal healthcare and contributing to improving the accessibility of animal medicines. In the innovative drug field, the Group's internationalisation strategy continues to deepen. Following the successful overseas licensing of UBT251 injection, several other key innovative drug projects are actively seeking and exploring opportunities for external collaboration. The Group will continue to deepen its global strategic layout, striving to provide more comprehensive treatment options and drug choices for patients worldwide, and making active contributions to enhancing drug accessibility. In March 2025, the Group entered into an exclusive licensing agreement with Novo Nordisk A/S. Under the licence agreement, Novo Nordisk will obtain exclusive rights to develop, manufacture and commercialise UBT251 worldwide, excluding Mainland China, Hong Kong, Macau and Taiwan, while United Bio will retain the rights to UBT251 in Mainland China, Hong Kong, Macau and Taiwan. UBT251 is a Class 1 innovative drug developed by United Bio. It is a long-acting GLP-1/GIP/GCG triple-target receptor agonist with potent activity at the glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon receptors, regulating appetite and energy metabolism, lowering blood glucose and body weight, and improving hepatic steatosis. To date, UBT251 has received approval in China and/or the United States to conduct clinical trials for the treatment of type 2 diabetes mellitus, overweight or obesity, metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease (CKD) and obstructive sleep apnoea (OSA). UBT251 Injection Achieves Out-Licensing 8.2.2 Medical Affordability The United Laboratories is fully aware that pharmaceutical pricing is directly related to patients' access to and affordability of medicines and is a key part of fulfilling our mission of “To Make Life More Valuable”. We insist on balancing sustainable corporate development with social value by establishing a scientific, transparent and fair pricing mechanism so that quality medicines can benefit more patients. To this end, during the Year the Group formally formulated and issued the United Laboratories Fair Pricing Policy, systematically establishing the core principles and management mechanisms for product pricing. 60 The United Laboratories International Holdings Limited 2025 Environmental, Social and Governance Report